GSK 2202083A
Alternative Names: GSK2202083A; Heptavalent combination vaccine - GSK; Heptavalent conjugated vaccine - GSKLatest Information Update: 18 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 27 Oct 2011 GlaxoSmithKline completes a phase II trial in Healthy infants in Canada, France and Germany (NCT01090453)
- 31 May 2010 Phase-II clinical trials in Diphtheria, Haemophilis infections, Hepatitis B, Meningococcal group C infections, Pertussis, Poliomyelitis and Tetanus (Prevention) in Germany (IM)
- 31 May 2010 Phase-II clinical trials in Diphtheria, Haemophilis infections, Hepatitis B, Meningococcal group C infections, Pertussis, Poliomyelitis and Tetanus (Prevention) in France (IM)